ParaX®: The Science Behind our Breakthroughs
Bringing precision to anti-parasitic drug discovery by combining multitude of experimental data.
Our Approach
Microtubules are a proven drug target, with microtubule-targeting agents (MTAs) successfully used to treat diseases like cancer. These dynamic filaments, essential for cell structure and division, also play a critical role in eukaryotic pathogens. Over time, parasites have evolved distinct microtubule modifications, setting them apart from their hosts. This unique divergence presents a powerful opportunity for targeted, host-safe therapies. By applying a proven strategy to a new frontier, we are pioneering breakthrough treatments that disrupt parasite microtubules with precision—without harming healthy cells.
OUR SOLUTION ParaX®
Our Precision Lead Generator
With our ParaX® Platform, we have perfected the technology to exploit subtle sequence differences between tubulins from parasite pathogens and hosts to enable specific inhibitor design by precision atomic scale drug engineering. We call these species-specific parasite inhibitors: Parabulins®.
Database
Knowledge
Assays
Expertise
Validation
Innovation
Optimization
Precision 2